Reversing Lp(a) and CV Risk: Antisense Oligonucleotides - FORD BREWER MD MPH
Recently published in NEJM (New England Journal of Medicine) is an article about antisense oligonucleotides. It's a new drug that reduces Lp(a) or lipoprotein (a) by up to 80%. This is more promising than current treatments, including niacin, L-carnitine, and apheresis. Still, the new antisense drug appears to be not yet ready for primetime. Here's the link to the NEJM article: https://www.nejm.org/doi/full/10.1056/NEJMoa1905239
Audio is streamed directly from the publisher (cdn.simplecast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
For more information, contact us at 859-721-1414 or [email protected]. Also, check out the following resources: